bearish

Teladoc Health Inc (TDOC US): 1Q22 Results Review- Revenue Missed, 2022 Guidance Reduced

238 Views28 Apr 2022 16:51
SUMMARY
  • Teladoc Health, Inc. (TDOC US) reported Q1 results, in-line with its prior guidance. However, 2022 guidance cut has played the spoilsport.
  • Teladoc shares plummeted more than 40% in 2022 to trade near 52-week low. With the near-term noises persist, shares will need time to recover.
  • With the current market dynamics in certain areas of operation not in favor of Teladoc, recent downfall in shares does not represent an attractive buying opportunity.
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Analytics & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x